Interleukin-6: Catabolic Agent or Growth Factor?

Most analyses of strength training are concerned with two phases: the work phase where we apply physical stress to our muscles to cause microtrauma and resulting overcompensation, and the anabolic phase in which we seek to enhance protein synthesis. But there's a third phase, a period of breakdown and recovery, which is rarely discussed. We are told to rest and to do what we can to avoid cortisol, but very seldom is there any mention of the signal molecules which accomplish the work of bringing the body back to a state of homeostasis.

Weightlifters talk of "destroying" their legs in a squat workout; of loading the muscles with weight and stressing them until they are barely able to function. What are the mechanisms that permit the body to recover from such punishment? Is it possible to optimize recovery so that less tissue is broken down, and we get into the anabolic phase more quickly?

The essay that follows will deal with some very technical concepts. I'm including a glossary containing brief definitions for the scientific terms used. The purpose of such a technical essay is twofold: First, it introduces some basic ideas in cell biology that will enable a better understanding of exercise physiology. Once the basic concepts are learned, one can view this area of science not as a collection of disparate facts, but as a coherent system that runs on a logical -- but complicated -- basis. Secondly, by going into detail concerning the stages whereby the body detects damage, disposes of damaged tissue, and ultimately replaces or strengthens the affected tissue, we can identify areas where we can intervene with nutrition or chemical agents to reduce damage and enhance our muscular gains. Also, it may be possible to take advantage of this intimate knowledge to design training protocols that coincide with the catabolic and anabolic stages that follow exercise.

There are four types of signaling molecules in the body: neurotransmitters, endocrine hormones, autacoids and cytokines. Cytokines are soluble proteins which act non-enzymatically to regulate cell function. There are various types of cytokines, among them being interleukins, hematopoietic regulators, interferons, growth and differentiation factors and chemotactic polypeptides. Interleukins (abbreviated IL) are cytokines that are produced by leukocytes (white blood cells) and that function during inflammatory responses. They may also be produced by other types of cells. Typically, interleukins have the twin properties of pleiotropy and redundancy. Pleiotropy means that an interleukin may have several different effects, depending on the environment and the tissue acted upon. Redundancy in this case refers to the ability of other cytokines (interleukins or not) to produce some of the same effects as the interleukin being studied. This redundancy can be due to the fact that receptors for interleukins often share common subunits, or it may also be caused by identical effects on transcription factors or on the DNA itself.

As of October 1998, eighteen different ILs have been described. We'll be focusing on interleukin-6 (IL-6), which has some special properties that make it interesting to bodybuilders. For those who might be curious, here is a brief survey of all the interleukins:

Figure 1.IL-6 molecule

IL-1 An inflammatory cytokine. One of the first cytokines to be secreted following trauma, infection, etc. Induces IL-6.

IL-2 Secreted by Type 1 T-helper cells (Th1) of the immune system. Stimulates cell-mediated (as opposed to antibody-mediated) immunity. Generally a beneficial cytokine. IL-2 levels decline with age, but are upregulated by DHEA.

IL-3 Growth factor for hematopoietic cells. Acts in a similar fashion as granulocyte-macrophage colony-stimulating factor (GM-CSF). Secreted by activated T lymphocytes, it induces formation of macrophages, neutrophils, etc. Also induces secretion of immunoglobulin from B cells.

IL-4 Anti-inflammatory cytokine. Related to IL-13. Released by activated T cells, it initiates the humoral response (antibodies).

IL-5 A B-cell growth and differentiation factor; also stimulates eosinophil precursor proliferation and differentiation. Secreted by activated T cells.

IL-6 Pro- (and sometimes anti-) inflammatory cytokine. Pleiotropic. The subject of this article. Main signal of cellular injury, and main mediator of the body's response to injury. Most important stimulator of acute phase proteins. Has an important role in hematopoiesis. Produced by a variety of cells.

IL-7 Growth factor produced by a number of different cells. Unlike other interleukins, IL-7 in not redundant, i.e. its function can not be duplicated by other cytokines. It is required for lymphocyte development.

IL-8 Pro-inflammatory. A chemokine. Can be induced by IL-1 and lipopolysaccharide from bacteria. Produced by many different cells.

IL-9 Cytokine produced by T cells, particularly when mitogen stimulated, that stimulates the proliferation of erythroid precursor cells. May act synergistically with erythropoietin. Synergizes with IL-4 to produce immunoglobulins.

IL-10 Anti-inflammatory. Produced by Th2 cells, plus some B cells and monocytes. Stimulates growth of stem cells and thymocytes. Stimulates B and T cell development. Suppresses cytokine production by macrophages.

IL-11 Pleiotropic cytokine originally isolated from bone marrow. Stimulates B cell maturation, and production of erythrocytes (red blood cells) and megakaryocytes. Synergizes with IL-3. Induces synthesis of acute-phase proteins in the liver.

IL-12 Formerly known as Natural Killer Cell Stimulatory Factor (NKSF). Produced by monocytes, macrophages, B cells, NK cells. Acts synergistically with IL-2 to transform T cells into cytotoxic T lymphocytes (CTLs). Stimulates the proliferation of activated T cells and NK cells and induces them to produce interferon-gamma.

IL-13 Anti-inflammatory. Related to IL-4. Produced by activated Th2 cells. Inhibits IL-6. Stimulates antibody production.

IL-14 A high molecular weight B lymphocyte growth factor. One of the least researched cytokines.

IL-15 Anabolic for skeletal muscle. IL-15 receptor contains some sub-units with the IL-2 receptor.

IL-16 Pro-inflammatory. Formerly called Lymphocyte Chemoattractant Factor.

IL-17 Pro-inflammatory. Produced by T cells. Activates NF-kappaB.

IL-18 Pro-inflammatory. Induces the cytokine interferon-gamma.

After acute or short-term exercise, the total number of lymphocytes increases, but if the exercise is intense and of long duration the number of lymphocytes decreases (Pedersen1997). A lack of glutamine resulting from exercise stress can impair the ability of lymphocytes to proliferate and to function (Sharp1992, Rohde1998).

Prolonged low intensity exercise may lower levels of interleukin-6 in the blood (Boyum1996), while intense or eccentric (negative) exercise causing muscle damage induces a dramatic rise in this cytokine (Bruunsgaard1997, Weinstock1997, Ullum1994).

In short, intense exercise increases cytokines which may act to break down muscle, while extensive exercise decreases cell- mediated immunity (i.e. the ability of Natural Killer cells, cytotoxic T lymphocytes, and phagocytes to eliminate potentially harmful cells and materials).

The human immune system is a network of active and passive defenses against substances and cells that would harm the body. It includes innate immunity from barriers like the skin, body temperature, pH (acidity) of the stomach, the inflammatory response and the action of phagocytic cells. It also includes acquired immunity, which is usually based on recognition and response to an antigen. This generally involves white blood cells called lymphocytes. There are two kinds: T cells (from the thymus) and B cells (from the bone marrow). Acquired immunity may be humoral, meaning it involves substances like antibodies and cytokines that are dissolved or suspended in the blood, or it may be cell-mediated, involving the cytotoxic activity of specialized cells.

Because the effects of exercise on the immune system do not involve antigens, such immune activity is fundamentally different from what you might read about in a text on immunology. 

During exercise, free radicals known as reactive oxygen intermediates (ROIs) and reactive nitrogen intermediates (RNIs) are formed. Additionally other reactive intermediates such as carbonyls may be produced. All these free radicals can signal and in some cases activate cells of the immune system.

When intense exercise causes damage to cells, the contents of the breached cell enters the surrounding lymph. This also has the effect of signalling that there has been damage.

Monocytes are white blood cells with a single nucleus that are formed in the bone marrow. When they arrive in the tissues of the body they may differentiate (mature) into macrophages, and lose some of their motility (ability to move independently). Muscle tissue contains a number of macrophages, and these are the first immune cells to react to exercise trauma. When a macrophage is activated, it undergoes a "respiratory burst" of oxidation, which produces even more ROIs, thus extending the signal to surrounding cells. Macrophages also secrete signal molecules like IL-8 which act as chemokines to attract other immune cells, in a process called chemotaxis.

Prostaglandins are secreted by macrophages as well. These, plus some metabolic byproducts of exercise like lactic acid, physical changes involved in pumping the muscle, and the effects of the first immune phenomena just described, combine to initiate inflammation in the effected muscles.

The first cytokines to be released as a result of exercise are the "pro-inflammatory" substances interferon-gamma (IFN-gamma), tumor necrosis factor (TNF) and interleukin-1 (IL-1). Also the chemokine IL-8 is released. IFN-gamma, TNF and IL-1 have a number of different effects on the body. They travel through the bloodstream and stimulate the liver to synthesize acute phase proteins like C-reactive protein, serum amyloid A and fibrinogen. They influence complement, which is yet another factor in the immune system, and kinins, which can produce vasodilation, pain, and may make you lose your lunch in the squat rack. They cause body temperature to increase. Most important for this article, all three act on T lymphocytes to cause them to secrete interleukin-6.

A second part of the cytokine cascade derives from activated lymphocytes. As we've mentioned, under normal exercise conditions, immune cells are not activated by antigens. There are alternative methods by which they can be activated. For example, lymphocyte proliferation can be artificially stimulated with a chemical that increases the level of glutathione, an antioxidant (Berridge1997). Also it is known that reactive oxygen intermediates like hydrogen peroxide ( H2O2 ) can activate the nuclear transcription factor NF-kappaB. So there is good reason to expect that the reduction/oxidation changes resulting from exercise may result in T cell activation.

Also it is known that certain cytokines can activate lymphocytes. For example, IL-1 was originally called "Lymphocyte Activating Factor."

Cytokines and acute phase proteins have a brief half- life in the body, so even without anti-inflammatory signalling this phase would inevitably end. However a number of substances produced by the body have the effect of bringing it to a conclusion more quickly.

As we all know, cortisol is secreted as a result of exercise. A product of the adrenal glands, cortisol is a member of a class of compounds called glucocorticoids. We normally think of glucocorticoids as being catabolic, but they also has the effect of inhibiting the synthesis of all acute phase cytokines. Since many of those cytokines are catabolic, this is actually an anti-catabolic action of cortisol. To put this in another way: if you are successful in limiting cortisol production after a workout, you might find an increased level of cytokines, and thus no net prevention of muscle loss!

Cytokines sometimes have soluble receptors. One way these are produced is from membrane receptors that are cleaved and "shed" from cells. The receptors then circulate in the blood. Soluble receptors for IL-1, IL-4 and TNF have the effect of binding to and thus deactivating their cytokines. You might say they "mop up" the cytokine. The production of these soluble receptors is a second way in which the body limits the acute phase. On the other hand, soluble receptors for IL-6 have the opposite effect: they can cause IL-6 metabolic effects on cells with incomplete receptors that normally wouldn't be effected.

A protein called IL-1 receptor antagonist (IL-1Ra) binds to IL-1 receptors, blocking the effect of IL-1. IL-1Ra is secreted from cells upon stimulation by TNF, and its production is enhanced by IL-10 and IL-4. As levels of these last interleukins rise, IL-1 declines.

IL-10, IL-4 and IL-13 are anti-inflammatory cytokines. They inhibit the production of inflammatory cytokines and also reduce induction of cyclooxygenase-2 (COX2), an enzyme involved in inflammation which is the target of drugs like aspirin. Whereas IL-1 and TNF are produced early in the acute phase response, the anti-inflammatory cytokines come from activated T cells, so they are a way in which the body gracefully concludes the acute phase.

IL-6 belongs to a family of physically similar or "homologous" cytokines, including Leukemia Inhibitory Factor (LIF), Ciliary Neurotropic Factor (CNTF), Granulocyte-Colony Stimulating Factor (G-CSF), IL-11, Oncostatin M (OSM), and Cardiotropin-1 (CT-1). IL- 6 type cytokines feature four anti-parallel helices, arranged as shown in Figure 1.

Receptors for IL-6 family cytokines are mulitimeric, having a specific component for binding with the cytokine, plus a transmembrane transducer protein called gp130 for delivering the signal to the nucleus of the cell. For example, the LIF receptor is composed of a gp130 molecule plus a specific component called LIFR-beta. IL-6 receptor is a trimer, with two gp130 molecules, plus a specific component called IL-6R-alpha. When IL-6 first contacts the cell, it binds with IL-6R-alpha. Then the gp130 molecules dimerize and bind with it to form the ligand-receptor complex.

Once the IL-6 receptor complex is assembled and bound, chemicals within the cells called Janus kinases (JAK) phosphorylate the amino acid tyrosine on the gp130 molecules. We have an effective tyrosine kinase inhibitor (genistein) that can block this process. We'll return to genistein in the section on IL-6 blockers, below.

The phosphotyrosines link up with a substance previously termed "acute phase response factor" (APRF), but which is now called STAT3 (for "Signal Transducer and Activator of Transcription"). STAT1 and STAT3 become phosphorylated and dimerize. Then these dimers travel to the nucleus of the cell. Meanwhile the IL-6/IL-6R-alpha combination is taken into the cell ("endocytosed") and is broken down and destroyed. The gp130 units are recycled.

The STAT dimers bind with IL-6 response elements which then activate gene transcription factors.

NF-IL-6 (Nuclear Factor IL-6) is a member of the C/EBP (CAAT/Enhancer Binding Protein) family of transcription factors. It is almost undetectable in normal circumstances, but when cells are stimulated with IL-6 it is produced abundantly. C/EBP regulates fat tissue. It increases differentiation from pre-adipocytes to adipocytes, activates the glucose transporter GLUT4, etc. In short, it makes you fat. When adipose tissue is treated with TNF -- which reduces fat -- C/EBP is reduced, but NF-IL6 increases. It seems that the ratio of C/EBP to NF-IL-6 is a determinant of fatness. Both IL-6 and LIF are known to drastically reduce fat, so the activation of NF-IL-6 may be one of the mechanisms of that fat reduction.

STAT3 can also bind to the IL-6 response element of the junB gene (JRE-IL6).

Apart from the JAK/STAT pathway, there is a second pathway from the IL-6 receptor to the nucleus. It involves a protein called ras, and Mitogen Activated Protein Kinase (MAPK).

NF-kappaB deserves special mention. The name derives from its discovery in B cells expressing kappa immunoglobulin. Subsequently it was found that NF-kappaB exists in nearly all mammalian cells. It regulates inflammation, immune reactions and acute phase response, and it is generally bad news for athletes. Elderly people and people with AIDS or chronic inflammation may have NF-kappaB almost permanently activated, which accounts for some of the tissue loss and poor health in those groups. On the other hand, NF-kappaB regulated genes encode hematopoietic growth factors, which can be useful to athletes.

Nuclear Factor kappa B

NF-kappaB is activity is low is a normal cell, due to an inhibitor named I-kappa-B. IL-1 and TNF act to degrade I-kappa- B, and by this means NF-kappaB is activated. As a result of transcription regulated by NF-kappaB, many cytokines -- including Il-6 -- are expressed. This is one way that IL-1 and TNF induce the secretion of Il-6. NF-kappaB can also be activated by reactive oxygen intermediates, and by IL-6 as described in the previous section.

There are several effective methods of inhibiting NF-kappaB, some of which will be described below.

This same trauma results in the expression of IL-6, LIF, and Fibroblast Growth Factor (FGF). These three act as growth factors (yes, in this case IL-6 is a growth factor), increasing the proliferation of myoblasts. See Figure 3: response of IL-6 and LIF to muscle injury (source: Kurek1996). LIF is a stronger inducer of proliferation than IL-6, and whereas the effect of IL-6 is short-lived, a brief exposure to LIF will result in proliferation over an extended period. Injections of LIF have been suggested as a therapy for muscle trauma and disease (Kurek1996).

Experiments on mice that were reported in 1989 and 1990 showed LIF inhibits the action of lipoprotein lipase (LPL), which is instrumental in uptake of fatty acids by adipose tissue (Hilton1992). A "dramatic and rapid loss of virtually all subcutaneous and abdominal fat" was reported. More recently, it has been shown that while administration of recombinant IL-6 to mice reduces LPL, it has almost no effect on fat reduction in mice (Fujita1996).

There are three main proteolytic pathways in skeletal muscle: cathepsins functioning in the lysosome, calpain proteases in the cell's cytosol, and the ATP-ubiquitin (Ub) pathway. IL-6 acts to destroy muscle through the cathepsin and ATP-Ub pathways. Fujita et al. showed that mice inoculated with a cancer (adenocarcinoma) developed high levels of IL-6 after 11 days: while untreated control mice had a level of 7.9 pg/ml of IL- 6, inoculated mice had an average of 1,142 pg/ml (Fujita1996). These inoculated mice had cathepsin B levels 236% higher, and cathepsin B levels 826% higher than controls. Tsujinaka et al. showed that in transgenic mice carrying DNA for human IL-6, treated mice had cathepsin B levels 20 times higher than controls (Tsujinaka1996).

IL-6 shortens the half-life of proteins in the myotubes that make up muscle fibers. It has been demonstrated that mRNA levels of proteosomes, which are involved with the ATP-Ub pathway, are increased by IL-6 (Ebisui1995, Tsujinaka1996). Strangely, TNF, which is often named as the main culprit in cachexia (wasting syndrome), has not been shown to have this effect. In fact, several studies have failed to show a direct effect by TNF on muscle proteolysis (reviewed in Fujita1996). Therefore it seems that the proteolytic action of TNF may actually be mediated through IL-6. In other words, without IL-6, TNF would not destroy muscle (although it would reduce fat). Therefore, IL-6 appears to be the primary agent in muscle wasting.

IL-6 is a catabolic agent in many disease states (Papanicolaou1998). It is present in rheumatism and other autoimmune type diseases, and is responsible for joint deterioration and muscle loss. DeBenedetti et al. found that transgenic mice with human IL-6 had stunted growth, attaining only about half the size of normal mice (Figure2). They also showed that in humans as well as mice, there is a negative correlation between IL-6 and IGF-1. In other words, the more IL-6 in the body, the less IGF-1. This relationship was unique to IL- 6: TNF and IL-1 were not correlated with IGF-1 (DeBenedetti1997).

In summary, the effects of IL-6 are mostly harmful for athletes. It plays beneficial roles in resisting infection, stimulating the acute phase response in case of trauma, and in hematopoiesis and production of stem cells. However, excessive IL-6 resulting from exercise or chronic inflammation will destroy muscle tissue and reduce IGF-1.

Now that we know the actions and effects of interleukin-6, let's consider ways to manipulate IL-6 secretion.

In the unlikely event that we'd want more IL-6, the method is obvious: just exercise. Any exercise that causes trauma to the muscles would suffice. If we want to start an acute phase response without the temporary immune suppression caused by exercise, there are herbs like Echinaceae and Rudbeckia speciosa that contain polysaccharides the body mistakes for bacteria, so that they can initiate an immune response (Bukovsky1995).

Caloric restriction is perhaps the simplest method of reducing IL-6 (Volk1994). This is a technique employed by life- extensionists. It might have some application to dieting athletes, providing they don't use weight-loss drugs.

Oils and fatty acids.

oEicosapentaenoic acid (EPA) supplementation significantly reduced IL-6 ecretion from mononuclear cells in patients with cancer (Wigmore1997).

oSupplementation with docosahexaenoic acid (DHA) and EPA reduced production of IL-1, IL-6, TNF and IL-2 by mononuclear cells in normal individuals and in patients with Rheumatoid Arthritis and with Multiple Sclerosis (Calder1997).

o The fatty acids gamma linolenic acid (GLA), EPA and DHA reduce serum IL-1, IL-2, IL-4, IL-6, TNF alpha and IFN-gamma in cancer patients. Three months after cessation of fatty acid supplementation cytokine values returned to normal (Purasiri1994).

o In human endothelial cells, DHA decreased secretion of IL- 6, IL-1, IL-4, IL- 8 and TNF (DeCaterina1994).

o Blackcurrant seed oil rich in GLA reduced production of IL- 1 beta, TNF alpha IL-6 and PGE2 (Watson1993).

Sources of GLA: evening primrose oil, borage seed oil, blackcurrant seed oil.

Sources of EPA and DHA: fish oils (e.g. cod liver oil, salmon oil, etc.).

Lactoferrin (found in milk) reduces IL-6 (Mattsby1996).

Estrogen and androgens reduce IL-6 and block NF-kappaB. Therefore, foods like soy which are estrogenic and supplements like androstenedione would be expected to have a similar effect.

Since one of the signal pathways from the IL-6 receptor depends on tyrosine kinase, genistein, which is an effective tyrosine kinase inhibitor, should block it. Genistein is a component of soy, and can be purchased in purified form.

Zinc induces Heat Shock Protein HSP-70 and reduces cytokines and apoptosis (Klosterhalfen1997).

Antioxidants. Since antioxidants provide some of the initial signals in the acute phase response, and since NF-kappaB can be directly activated by reactive oxygen intermediates, antioxidants can prevent secretion of IL-6 and the effects of NF-kappaB transcription.

o Vitamin E supplementation (400 units twice per day) almost completely eliminated increased secretion of Il-6 in athletes following three 15 minute sets of downhill running (Cannon1991).

o L-ascorbic acid inhibits secretion of IL-1 and IL-6 (Tebbe1997).

o Black tea extract lowers concentrations of IL-6 (Amarakoon1995).

o Melatonin reduces oxidative stress, improves immune function. etc. (Reiter1997).

o Since expression of IL-6 mRNA is dependent on NF-kappaB binding to the IL-6 gene, supplementation with the antioxidant N-acetyl-L-cysteine (NAC) can block the process (Shibanuma1994).

o A number of experimental antioxidants have been employed in studies of NF-kappaB inhibition. They include glutathione, NADPH, pyrrolidine dithiocarbamate (PDTC), butylated hydroxyanisole (BHA), and various forms of superoxide dismutase.

Since IL-1, IFN-gamma, and TNF induce IL-6 production, any substances that inhibit them will usually have the effect of inhibiting Il-6.

NF-kappaB can be inhibited by nitric oxide (NO). One substance that induces NO is the amino acid arginine.

Aspirin and salicylate inhibit NF-kappaB. Also salicylate inhibits protein kinase activity, and so would prevent signalling by IL-6 via tyrosine kinase (Beauparlant1996). Since methyl salicylate is a common ingredient of ointments for sore muscles, this raises the possibility that a topical application could be effective against IL-6.

There is a negative correlation between dehydroepiandrosterone sulfate (DHEAS) and IL-6 in the blood (Straub1998). Therefore supplementation with DHEA will reduce IL-6.

Since IL-6 is a factor in many diseases, a number of drugs and pharmaceutical techniques have been investigated for lowering IL- 6 levels. Some of the substances mentioned below are experimental or unapproved.

Glucocorticoids like dexamethasone block transcription factors NF-kappaB and AP-1 (Brattsand1996). Unfortunately they are also catabolic to muscle, and so are of little use to the athlete, except in case of injury.

RU486 (mifepristone) can block NF-kappaB induced by TNF, although not as well as glucocorticoids (Beauparlant1996). It has the advantage that it also blocks glucocorticoid receptors, but unfortunately the receptors soon upregulate.

The immunosuppressant drugs FK506 and cyclosporin A will suppress T cells, but this would be an insane way to inhibit IL-6, due to the side effects.

Anti-inflammatory cytokines like IL-10, IL-4, IL-13, and Transforming Growth Factor beta (TGF-beta) will inhibit synthesis of IL-6 and other inflammatory cytokines. IL-10 also enhances synthesis of IL-1 receptor antagonist, downregulates TNF receptors and inhibits T cell proliferation (Koj1998, Xing1997, Dokter1996).

Soluble cytokine receptors and receptor antagonists are effective against IL-1 and TNF, which induce IL-6. Unfortunately, the IL-6 soluble receptor only increases the effect of IL-6. Enbrel, a soluble receptor for TNF made by Immunex, will be on the market soon for treatment of rheumatoid arthritis and similar inflammatory conditions.

Rolipram, an antidepressant sold in Europe by Schering, is also very effective at inhibiting TNF, and so has an indirect effect on IL-6.

Tenidap, a new anti-rheumatic drug, showed a great deal of promise against cytokines, but the FDA decided not to approve it because of problems with proteinuria (protein in the urine). This side effect may make it unsuitable for athletes. It is available from Europe (Breedveld1994, Bondeson1996).

Polymyxin B administration results in a prompt reduction in interleukin-6 levels in burn patients (Cone1997).

For women, medroxyprogesterone acetate has reduced IL-6 in breast cancer patients. Reduction was correlated with plasma levels of MPA, not dosage (Yamashita1996).

Use of a monoclonal antibody against CD-54 (ICAM-1) reduced IL-6 in rheumatoid arthritis (RA) patients (Schulze1996).

Antibodies against TNF have been used to reduce IL-6 (Fekade1996).

Indomethacin reduces Il-6 by inhibiting prostaglandin E2 (Hinson1996).

Tyloxapol, a potent anti-oxidant used in the treatment of cystic fibrosis and chronic bronchitis, inhibits NF-kappaB and IL-6 (Ghio1996).

The anti-rheumatic drug minocycline decreases serum levels of IL-6 (Kloppenburg1996).

The anti-rheumatic drug tepoxalin inhibits the production of IL-2, IL-6 and TNF alpha and inhibits activation of NF- kappaB (Ritchie1995).

Pentoxifylline is a methylxanthine derivative that acts as a phosphodiesterase inhibitor and is prescribed to improve capillary flow. It inhibits TNF and IL-6 and counteracts the respiratory burst of phagocytes that produces free radicals (Lundblad1995), Koj1998, Mandell1995).

Torbafylline, a xanthine derivative that suppresses TNF, has been used with some experimental success in the treatment of cachexia (Sinha1995).

IL-6 is the main mediator of muscle wasting. It may have some beneficial actions at the onset of the acute phase response, but chronically high IL-6 levels must be avoided for good health and optimum muscular development. We have a number of ways to accomplish that, from the simple use of antioxidants to specially designed antibodies. Through the use of these agents in coordination with training activity, we can effectively reduce the unnecessary muscle breakdown that normally follows intense exercise.

1. Agnello D, Meazza C, et al. 1998 Sep. Leptin causes body weight loss in the absence of in vivo activities typical of cytokines of the IL-6 family. Am J Physiol. 275(3 Pt 2):R913-9.

2. Akira S, Yoshida K, Tanaka T, Taga T, Kishimoto T. 1995. Targeted disruption of the IL-6 related Genes: gp130 and NF-IL-6. Immunol Rev. 148:221-53.

3. Amarakoon AM, Tappia PS, Grimble RF. 1995. Endotoxin induced production of interleukin-6 is enhanced by vitamin E deficiency and reduced by black tea extract. Inflamm Res. 44:301-305.

4. Ambrus JL Jr, Pippin J, et al. 1993 Jul 1. Identification of a cDNA for a human high-molecular-weight B-cell growth factor. Proc Natl Acad Sci U S A. 90(13):6330-4.

5. Austin L, Burgess AW. 1991 Feb. Stimulation of myoblast proliferation in culture by leukaemia inhibitory factor and other cytokines. J Neurol Sci. 101(2):193-7.

6. Barnoy S, Glaser T, Kosower NS. 1998 Mar 12. The calpain-calpastatin system and protein degradation in fusing myoblasts. Biochim.Biophys.Acta 1402(1):52-60.

7. Baumann H, Onorato V, Gauldie J, Jahreis GP. 1987 Jul 15. Distinct sets of acute phase plasma proteins are stimulated by separate human hepatocyte-stimulating factors and monokines in rat hepatoma cells. J.Biol.Chem. 262(20):9756-68.

8. Baumann H, Morella KK, et al. 1996 Aug 6. The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc Natl Acad Sci U S A. 93(16):8374-8.

9. Beauparlant P, Hiscott J. 1996. Biological and biochemical inhibitors of the NF-kappaB/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev. 7(2):175-190.

10. Bellido T, Jilka RL, et al. 1995 Jun. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J.Clin.Invest. 95(6):2886-95.

11. Berkowitz DE, Brown D, et al. 1998 Jun. Endotoxin-induced alteration in the expression of leptin and beta3-adrenergic receptor in adipose tissue. Am J Physiol. 274(6):E992-E997.

12. Berridge MJ. 1997. Lymphocyte activation in health and disease. Crit Rev Immunol. 17:155-178.

13. Bischoff R. 1997 Apr. Chemotaxis of skeletal muscle satellite cells. Dev.Dyn. 208(4):505-15.

14. Blackwell TS, Christman JW. 1997 Jul. The Role of Nuclear Factor-kappa B in Cytokine Gene Regulation. Am J Respir Cell Mol Biol. 17(1):3-9.

15. Bondeson J. 1996. Effects of tenidap on intracellular signal transduction and the induction of proinflammatory cytokines: a review. Gen Pharmac. 27:943-956.

16. Boyum A, Wiik P, et al. 1996 Feb. The effect of strenuous exercise, calorie deficiency and sleep deprivation on white blood cells, plasma immunoglobulins and cytokines. Scand J Immunol. 43(2):228-35.

17. Brakenhoff JPJ, DeHon FD, Aarden LA. 1995 Jul 21. Development of human IL-6 receptor antagonists. Ann N Y Acad Sci. 762:129-135.

18. Brattsand R, Linden M. 1996. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther. 10(Suppl 2):81-90.

19. Breedveld F. 1994. Tenidap: a novel cytokine-modulating antirheumatic drug for the treatment of rheumatoid arthritis. Scand J Rheumatol Suppl. 100:31-44.

20. Bruunsgaard H, Galbo H, et al. 1997 Mar 15. Exercise-induced increase in serum interleukin-6 in humans is related to muscle damage. J Physiol (Lond). 499 ( Pt 3):833-41.

21. Bukovsky M, Vaverkova S, Kost'alova D. 1995 Mar-Apr. Immunomodulating activity of Echinacea gloriosa L., Echinacea angustifolia DC. and Rudbeckia speciosa Wenderoth ethanol-water extracts. Pol J Pharmacol. 47(2):175-7.

22. Calder, PC. 1997. n-3 polyunsaturated fatty acids and cytokine production in health and disease. Ann Nutr Metab 41: 203-234

23. Cannon JG, Meydani SM, et al. 1991. Acute phase response in exercise. II. Associations between vitamin E, cytokines, and muscle proteolysis. Am J Physiol. 260:R1235-R1240.

24. Cannon JG, Fiatarone MA, Fielding RA, Evans WJ. 1994 Jun. Aging and stress-induced changes in complement activation and neutrophil mobilization. J.Appl.Physiol. 76(6):2616-20.

25. Center DM, Kornfeld H, Cruikshank WW. 1997 Nov. Interleukin-16. Int J Biochem Cell Biol. 29(11):1231-4.

26. Cone JB, Wallace BH, Lubansky HJ, Caldwell FT. 1997. Manipulation of the inflammatory response to burn injury. J Trauma 43:41-45.

27. DeBenedetti F, Alonzi T, et al. 1997 Feb. Interleukin 6 Causes Growth Impairment in Transgenic Mice through a Decrease in Insulin-like Growth Factor-I: A Model for Stunted Growth in Children with Chronic Inflammation. J. Clin. Invest. 99(4):643-650.

28. De Caterina R, Cybulsky MI, et al. 1994. The omega-3 fatty acid docosahexaenoate reduces cytokine- induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler Thromb. 14:1829-1836.

29. Dendorfer U, Oettgen P, Libermann TA. 1994. Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol Cell Biol. 14:4443-4454.

30. Dinarello CA, Novick D, Puren AJ, Fantuzzi G, Shapiro L, et al. 1998 Jun. Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leukoc Biol. 63(6):658-64.

31. Dokter WA, Koopmans SB, Vellenga E. 1996. Effects of IL-10 and IL-4 on LPS-induced transcription factors (AP-1, NF-IL6 and NF- kappa B) which are involved in IL-6 regulation. Leukemia. 10:1308- 1316.

32. Ebisui C, Tsujinaka T, et al. 1995. Interleukin-6 induces proteolysis by activating intracellular proteases (cathepsins B and L, proteasome) in C2C12 myotubes. Clin Sci (Colch). 89(4):431-9.

33. Engelhardt M, Kumar R, et al. 1997 Jul 1. Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood. 90(1):182-93.

34. Fekade DK, Knox K, et al. 1996. Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N Engl J Med. 335:311-315.

35. Fujita J, Tsujinaka T, et al. 1996. Anti-interleukin-6 receptor antibody prevents muscle atrophy in colony-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int J Cancer. 68:637-643.

36. Ghio AJ, Marshall BC, et al. 1996. Tyloxapol inhibits NF-kappa B and cytokine release, scavenges HOCI, and reduces viscosity of cystic fibrosis sputum. Am J Respir Crit Care Med. 154:783-788.

37. Heinrich PC, Horn F, Graeve L, Dittrich E, Kerr I, Müller-Newen G, Grötzinger J, Wollmer A. 1998. Interleukin-6 and related cytokines: effect on the acute phase reaction. Z Ernährungswiss. 37(Suppl 1):43-49.

38. Hibi M, Nakajima K, Hirano T. 1996. IL-6 cytokine family and signal transduction: a model of the cytokine system. J Mol Med. 74:1-12.

39. Hilton DJ. 1992 Feb. LIF: lots of interesting functions. TIBS. 17:72-76.

40. Hinson RM, Williams JA, Shacter E. 1996. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci USA. 93:4885-4890.

41. Hirano T, Nakajima K, Hibi M. 1997. Signaling mechanisms through gp130 : a model of the cytokine system. Cytokine Growth Factor Rev. 8:241-252.

42. Hirano T. 1998. Interleukin 6 and its receptor: Ten years later. Internat Rev Immunol. 16:249-284.

43. Husebekk A, Stenstad T, et al. 1996. Experimental AA-amyloidosis in mice is inhibited by treatment with the anti-rheumatic drug tenidap. Scand J Immunol. 43:551-555.

44. Ironson G, Field T, et al. 1996 Feb. Massage therapy is associated with enhancement of the immune system's cytotoxic capacity. Int J Neurosci. 84(1-4):205-17.

45. Klahr S, Morrissey J. 1998 (Jan). Angiotensin II and gene expression in the kidney. Am J Kidney Dis. 31(1):171-6.

46. Kloppenburg M, Dijkmans BA, et al. 1996. Inflammatory and immunological parameters of disease activity in rheumatoid arthritis patients treated with minocycline. Immunopharmacology. 31:163-169.

47. Klosterhalfen B, Hauptmann S, et al. 1997. Induction of heat shock protein 70 by zinc-bis-(DL- hydrogenaspartate) reduces cytokine liberation, apoptosis, and mortality rate in a rat model of LD100 endotoxemia. Shock. 7:254-262.

48. Koj A. 1996. Initiation of acute phase response and synthesis of cytokines. Biochim Biophys Acta. 1317:84-94.

49. Koj A. 1998. Termination of acute-phase response: role of some cytokines and anti-inflammatory drugs. Gen Pharmac. 31(1):9-18.

50. Kurek JB, Nouri S, Kannourakis G, Murphy M, Austin L. 1996. Leukemia inhibitory factor and interleukin-6 are promoted by diseased and regenerating skeletal muscle. Muscle Nerve. 19:1291-1301.

51. Lai CF, Ripperger J, Morella KK, Jurlander J, Hawley TS, Carson WE, Kordula T, Caligiuri MA, Hawley RG, Fey GH, Baumann H. 1996 Jun 14. Receptors for interleukin (IL)-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements. J.Biol.Chem. 271(24):13968-75.

52. Leon LR, White AA, Kluger MJ. 1998 Jul. Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. Am J Physiol. 275(1):R269-R277. (Full text - subscription required)

53. Lin SC, Yamate T, Taguchi Y, Borba VZ, Girasole G, O'Brien CA, Bellido T, Abe E, Manolagas SC. 1997 Oct 15. Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow. J Clin Invest. 100(8):1980-90.

54. Lundblad R, Ekstrom P, Giercksky KE. 1995. Pentoxifylline improves survival and reduces tumor necrosis factor, interleukin-6, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Shock. 3:210-215.

55. Mandell GL. 1995. Cytokines, phagocytes, and pentoxifylline. J Cardiovasc Pharmacol 25 Suppl 2: S20-S22.

56. Mattsby-Baltzer I, Roseanu A, Motas C, Elverfors J, Engberg I, Hanson LA. 1996. Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells. Pediatr Res. 40:257-262.

57. Mertsching E, Meyer V, Linares J, Lombard-Platet S, Ceredig R. 1998. Interleukin-7, a non-redundant potent cytokine whose over-expression massively perturbs B-lymphopoiesis. Int Rev Immunol. 16(3-4):285-308.

58. Nieman DC. 1997 May. Immune response to heavy exertion. J Appl Physiol. 82(5):1385-94.

59. Ounissi-Benkalha H, Pelletier JP, et al. 1996. In vitro effects of 2 antirheumatic drugs on the synthesis and expression of proinflammatory cytokines in synovial membranes from patients with rheumatoid arthritis. J Rheumatol. 23:16-23.

60. Papanicolaou DA, Petrides JS, et al. 1996 Sep. Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlation with catecholamines. Am J Physiol. 271(3 Pt 1):E601-5.

61. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. 1998 Jan 15. The pathophysiologic roles of interleukin-6 in human disease. Ann.Intern.Med. 128(2):127-37.

62. Pedersen BK, Bruunsgaard H, et al. 1997 Mar. Exercise-induced immunomodulation--possible roles of neuroendocrine and metabolic factors. Int J Sports Med. 18(Suppl 1):S2-7.

63. Purasiri P, Murray A, Richardson S, Heys SD, Horrobin D, Eremin O. 1994. Modulation of cytokine production in vivo by dietary essential fatty acids in patients with colorectal cancer. Clin Sci (Colch.) 87:711-717.

64. Quinn LS, Haugk KL, Grabstein KH. 1995 Aug. Interleukin-15: a novel anabolic cytokine for skeletal muscle. Endocrinology. 136(8):3669-72.

65. Reiter RJ, Carneiro RC, Oh CS. 1997 Aug. Melatonin in relation to cellular antioxidative defense mechanisms. Horm Metab Res. 29(8):363-72.

66. Ritchie DM, Argentieri DC, et al. 1995. Cytokine-modulating activity of tepoxalin, a new potential antirheumatic. Int J Immunopharmacol. 17: 805-812.

67. Rohde T, MacLean DA, Richter EA, Kiens B, Pedersen BK. 1997. Prolonged submaximal eccentric exercise is associated with increased levels of plasma IL-6. Am J Physiol. 273:E85-E91.

68. Rohde T, MacLean DA, Pedersen BK. 1998 Jun. Effect of glutamine supplementation on changes in the immune system induced by repeated exercise. Med.Sci.Sports Exerc. 30(6):856-62.

69. Roubenoff R. 1997 May 5. Inflammatory and Hormonal Mediators of Cachexia. J Nutrition. 127(5):1014S-1016S.

70. Saba AA, Kaidi AA, et al. 1996. Effects of interleukin-6 and its neutralizing antibodies on peritoneal adhesion formation and wound healing. Am Surg. 62:569-572.

71. Sancéau J, Kaisho T, Hirano T. 1995 Nov 17. Triggering of the human interleukin-6 gene by interferon- and tumor necrosis factor- in monocytic cells involves cooperation between Interferon Regulatory Factor-1, NFB, and Sp1 transcription factors. 270(46): 27920-27931.

72. Schulze-Koops H, Lipsky PE, Kavanaugh AF, Davis LS. 1996. Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis after treatment with a monoclonal antibody to CD54 (ICAM-1). Clin Exp Immunol. 106:190-196.

73. Sehgal PB, Wang L, Rayanade R, Pan H, Margulies L. 1995 Jul 21. Interleukin-6-type cytokines. Ann.N.Y.Acad.Sci. 762:1-14.

74. Sharp NC, Koutedakis Y. 1992 Jul. Sport and the overtraining syndrome: immunological aspects. Br.Med.Bull. 48(3):518-33.

75. Shephard RJ, Rhind S, Shek PN. 1994 Oct. Exercise and training: influences on cytotoxicity, interleukin-1, interleukin-2 and receptor structures. Int J Sports Med. 15 Suppl 3:S154-66.

76. Shibanuma M, Kuroki T, Nose K. 1994 Oct 10. Inhibition by N-acetyl-L-cysteine of interleukin-6 mRNA induction and activation of NF kappa B by tumor necrosis factor alpha in a mouse fibroblastic cell line, Balb/3T3. FEBS Lett. 353(1):62-6.

77. Sinha B, Semmler J, et al. 1995 Jan. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol. 25(1):147-53.

78. Speirs V, Adams EF, White MC. 1993. The anti-estrogen tamoxifen blocks the stimulatory effects of interleukin-6 on 17 beta- hydroxysteroid dehydrogenase activity in MCF-7 cells. J Steroid Biochem Mol Biol. 46:605-611.

79. Spencer NFL, Poynter ME, Hennebold JD, Mu HH, Daynes RA. 1995 Jul 21. Does DHEAS restore immune competence in aged animals through its capacity to function as a natural modulator of peroxisome activities? Ann N Y Acad Sci. 762:200-216.

80. Spriggs MK. 1997 Sep. Interleukin-17 and its receptor. J Clin Immunol. 17(5):366-9.

81. Stein B, Yang MX. 1995. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol Cell Biol. 15:4971-4979.

82. Straub RH, Konecna L, Hrach S, Rothe G, Kreutz M, et al. 1998. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab. 83:2012-2017.

83. Tartaglia LA, Dembski M, et al. 1995. Identification and expression cloning of a leptin receptor, OB-R. Cell. 83:1263-1271.

84. Tebbe B, Wu S, et al. 1997. L-ascorbic acid inhibits UVA-induced lipid peroxidation and secretion of IL-1alpha and IL-6 in cultured human keratinocytes in vitro. J Invest Dermatol. 108:302-306.

85. Tidball JG. 1995 Jul. Inflammatory cell response to acute muscle injury. Med.Sci.Sports Exerc. 27(7):1022-32.

86. Tsujinaka T, Fujita J, et al. 1996 Jan 1. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest. 97(1):244-9.

87. Ullum H, Haahr PM, et al. 1994 Jul. Bicycle exercise enhances plasma IL-6 but does not change IL-1 alpha, IL-1 beta, IL-6, or TNF-alpha pre-mRNA in BMNC. J Appl Physiol. 77(1):93-7.

88. Vaananen HK, Harkonen PL. 1996 May. Estrogen and bone metabolism. Maturitas. 23 Suppl:S65-S69.

89. Volk MJ, Pugh TD, et al. 1994. Dietary restriction from middle age attenuates age-associated lymphoma development and interleukin 6 dysregulation in C57BL/6 mice. Cancer Res 54:3054-3061.

90. Wang P, Wu P, Siegel MI, Egan RW, Motasim Billah M. 1995. Interleukin (IL)-10 Inhibits Nuclear Factor kappa B (NFKB) Activation in Human Monocytes.J Biol Chem. 270(16):9558-9563.

91. Watson J, Byars ML, et al. 1993. Cytokine and prostaglandin production by monocytes of volunteers and rheumatoid arthritis patients treated with dietary supplements of blackcurrant seed oil. Br J Rheumatol. 32:1055-1058.

92. Watson RR, Huls A, Araghinikuam M, Chung S. 1996 Oct. Dehydroepiandrosterone and diseases of aging. Drugs Aging. 9(4):274-291.

93. Weinstock C, Konig D, et al. 1997 Mar. Effect of exhaustive exercise stress on the cytokine response. Med Sci Sports Exerc. 29(3):345-54.

94. Wigmore SJ, Fearon KC, Maingay JP, Ross JA. 1997. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci (Colch.) 92:215-221.

95. Xing Z, Ohkawara Y, et al. 1997. Adenoviral vector-mediated interleukin-10 expression in vivo: intramuscular gene transfer inhibits cytokine responses in endotoxemia. Gene Ther 4:140-149.

96. Yamashita J, Hideshima T, Shirakusa T, Ogawa M. 1996. Medroxyprogesterone acetate treatment reduces serum interleukin-6 levels in patients with metastatic breast carcinoma. Cancer 78:2346-2352.

97. Yan SF, Tritto I, Pinsky D, Liao H, Huang J, Fuller G, Brett J, May L, and Stern D. 1995 May 12. Induction of Interleukin 6 (IL-6) by Hypoxia in Vascular Cells. J Biol Chem. 270(19):11463-11471